Telix Pharmaceuticals Limited (ASX:TLX) Reports $186M Q1 Revenue
Telix Pharmaceuticals Limited (ASX:TLX) reports a 62% increase in Q1 2025 revenue, reaching $186M.
Telix Pharmaceuticals Limited (ASX:TLX) reports a 62% increase in Q1 2025 revenue, reaching $186M.
Australasian Metals Limited (ASX:A8G) announces strategic portfolio rationalisation and exploration progress across multiple projects.
Tower (ASX:TWR) revises FY25 underlying NPAT upwards to $70m-$80m amid improved claims performance and strategic investments.
Clarity Pharmaceuticals (ASX:CU6) secures a copper-64 supply agreement with Nusano to support clinical trials and commercialization.
Anatara Lifesciences (ASX:ANR) reports Phase II GaRP-IBS trial results, highlighting safety and significant improvements in anxiety scores.
Dreadnought Resources Ltd (ASX:DRE) closes its Share Purchase Plan, raising $1.73M with strong shareholder support.
Podium Minerals (ASX:POD) completes the EV Nickel acquisition and becomes the first Australian PGM developer to join the World Platinum Investment Council.
Streamplay Studio (ASX:SP8) launches Sacre Bleu globally on Nintendo Switch and Steam, marking its first title on these platforms.
Pilbara Minerals (ASX:PLS) reports March quarter production of 125 kt, reduced revenue, and key project completions.
Mighty Kingdom Limited (ASX:MKL) issues a replacement prospectus for a non-renounceable entitlement offer, aiming to raise up to $1.08M to support operational growth and profitability.